Vascular calcifications and their poor association with metabolic bone disease in a hemodialysis population
Abstract
Introduction: Vascular calcifications are part of the mineral bone disorder in chronic kidney disease and they are one of the main causes of mortality. There is plausibility and experimental association between metabolic disorder and vascular calcification; however, there is no enough evidence for their clinical connection. Objective: To determine the association of biochemical alterations of mineral bone disorder (calcium: >10 mg/dL; phosphorus: >5 mg/dL; paratohormone: >300 pg/mL) with vascular calcifications evaluated according to the Kauppila score. Methods: An observational, cross-sectional, analytical study was performed. 97 stage V CKD patients undergoing hemodialysis were included; 69% were prevalent cases (diagnosed within >6 months) with an average time of 5.3 years. A statistical association was established according to Pearson's Chi2 test and logistic regression. Results: A level of vascular calcification was found with a Kauppila score of >1 in 60.8% of patients and of ≥3 in 43.3% of them, being predominant in the prevalent dialysis population (78.6%). However, no statistical association was found with mineral bone disorder in the chi-squared bivariate analysis or the logistic regression. Conclusions: A cross-sectional test of the biochemical alteration in mineral bone disorder does not allow to find an association with vascular calcifications. It is necessary to establish a prospective calcium-phosphorus positive balance first to prove this association.
References
2) Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol. 2004;15(12):2959-64.
3) Watanabe R, Lemos MM, Manfredi SR, Draibe SA, Canziani ME. Impact of cardiovascular calcification in nondialyzed patients after 24 months of follow-up. Clin J Am Soc Nephrol. 2010;5(2):189-94.
4) Amann K. Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(6):1599-605.
5) Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38(4):938-42.
6) Hruska KA, Mathew S, Lund RJ, Memon I, Saab G. The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature. Semin Nephrol. 2009;29(2):156-65.
7) Neven E, De Schutter TM, De Broe ME, D'Haese PC. Cell biological and physicochemical aspects of arterial calcification. Kidney Int. 2011;79(11):1166-77.
8) Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70(4):771-80.
9) Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(5):1423-9.
10) Castillo-Velarde E, Atusparia-Flores G, Reinoso-Trabucco C, Cruz-Huertas B, Ruiz-Carrasco B, Gallegos-Flores A, et al. Evaluación de las calcificaciones vasculares y trastorno mineral óseo de la ERC en hemodiálisis. Rev Fac Med Hum. 2018;18(3):39-46.
11) Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis. 1997;132(2):245-50.
12) Honkanen E, Kauppila L, Wikström B, Rensma PL, Krzesinski JM, Aasarod K, et al. Abdominal aortic calcification in dialysis patients: results of the CORD study. Nephrol Dial Transplant. 2008;23(12):4009-15.
13) Maruyama N, Higuchi T, Ono M, Oguma H, Nakamura Y, Utsunomiya K, et al. Correlation between aortic calcification score and biochemical parameters in hemodialysis patients. Contrib Nephrol. 2019;198:40-51.
14) Castillo Valverde ER. Informe EMO (enfermedad mineral ósea). Lima: Colegio Médico del Perú, 2015, p. 28-30.
15) Hill Gallant KM, Spiegel DM. Calcium balance in chronic kidney disease. Curr Osteoporos Rep. 2017;15(3):214-21.
16) Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int. 2012;81(11):1116-22.
17) Craver L, Marco MP, Martínez I, Rue M, Borràs M, Martín ML, et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges. Nephrol Dial Transplant. 2007;22(4):1171-6.
18) Talmage DW, Talmage RV. Calcium homeostasis: how bone solubility relates to all aspects of bone physiology. J Musculoskelet Neuronal Interact. 2007;7(2):108-12.
9) Talmage RV, Mobley HT. The concentration of free calcium in plasma is set by the extracellular action of noncollagenous proteins and hydroxyapatite. Gen Comp Endocrinol. 2009;162(3):245-50.
20) Phang JM, Berman M, Finerman GA, Neer RM, Rosenberg LE, Hahn TJ. Dietary perturbation of calcium metabolism in normal man: compartmental analysis. J Clin Invest. 1969;48(1):67-77.
21) Messa P, Cerutti R, Brezzi B, Alfieri C, Cozzolino M. Calcium and phosphate control by dialysis treatments. Blood Purif. 2009;27(4):360-8.
22) Palmer BF. Individualizing the dialysate in the hemodialysis patient. Semin Dial. 2001;14(1):41-9.
23) Felsenfeld AJ, Rodriguez M. Phosphorus, regulation of plasma calcium, and secondary hyperparathyroidism: a hypothesis to integrate a historical and modern perspective. J Am Soc Nephrol. 1999;10(4):878-90.
Copyright (c) 2020 Revista de Nefrología, Diálisis y Trasplante
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
